![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HMCN2 |
Gene summary for HMCN2 |
![]() |
Gene information | Species | Human | Gene symbol | HMCN2 | Gene ID | 256158 |
Gene name | hemicentin 2 | |
Gene Alias | HMCN2 | |
Cytomap | 9q34.11 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256158 | HMCN2 | C30 | Human | Oral cavity | OSCC | 1.00e-02 | 1.84e-01 | 0.3055 |
256158 | HMCN2 | ATC13 | Human | Thyroid | ATC | 2.00e-43 | 9.70e-01 | 0.34 |
256158 | HMCN2 | ATC5 | Human | Thyroid | ATC | 9.09e-50 | 1.03e+00 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMCN2 | SNV | Missense_Mutation | novel | c.487N>T | p.Val163Leu | p.V163L | Q8NDA2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.6817N>A | p.Pro2273Thr | p.P2273T | Q8NDA2 | protein_coding | tolerated(0.27) | benign(0.063) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
HMCN2 | SNV | Missense_Mutation | novel | c.2329N>T | p.Ile777Phe | p.I777F | Q8NDA2 | protein_coding | deleterious(0.01) | possibly_damaging(0.832) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
HMCN2 | SNV | Missense_Mutation | rs563941989 | c.13060N>A | p.Asp4354Asn | p.D4354N | Q8NDA2 | protein_coding | tolerated(1) | benign(0.34) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
HMCN2 | SNV | Missense_Mutation | rs371438649 | c.2258C>T | p.Ala753Val | p.A753V | Q8NDA2 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
HMCN2 | SNV | Missense_Mutation | novel | c.8041N>G | p.Trp2681Gly | p.W2681G | Q8NDA2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.15028N>A | p.Ala5010Thr | p.A5010T | Q8NDA2 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HMCN2 | SNV | Missense_Mutation | rs554164495 | c.11512G>A | p.Glu3838Lys | p.E3838K | Q8NDA2 | protein_coding | deleterious(0.03) | possibly_damaging(0.898) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
HMCN2 | SNV | Missense_Mutation | rs11244313 | c.5278G>A | p.Glu1760Lys | p.E1760K | Q8NDA2 | protein_coding | tolerated(0.2) | benign(0.042) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
HMCN2 | SNV | Missense_Mutation | novel | c.10309G>A | p.Glu3437Lys | p.E3437K | Q8NDA2 | protein_coding | tolerated(0.18) | possibly_damaging(0.554) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |